RxDoctor Payments Data

Jeffrey Tindall, DO

Family Medicine · Potosi, MONPI 1043281694

Payments from drug & device makers

$2,656in general payments, 2019–2025

Across 128 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Philips North America LLC$76
  • Boehringer Ingelheim$70
  • Sanofi-aventis U.S. LLC$53
  • GSK$35
  • Apria Healthcare LLC$34
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$2,63599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,656 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$12,730
Medicare patients
87
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol158$122,593
JardianceEmpagliflozin134$116,373
OzempicSemaglutide102$110,108
MounjaroTirzepatide103$109,866
EliquisApixaban116$94,756
VraylarCariprazine Hcl43$63,230
RybelsusSemaglutide51$58,061
TrulicityDulaglutide56$57,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$44,800
XareltoRivaroxaban45$41,378
MyrbetriqMirabegron81$39,555
LinzessLinaclotide47$32,575
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$29,261
Repatha SureclickEvolocumab43$25,360
JanuviaSitagliptin Phosphate35$24,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Stiolto Respimat$70$139,159170 claims
AbbVieVraylar, Linzess$2,346$95,80590 claims
GSKTrelegy Ellipta, Anoro Ellipta$35$56,51682 claims
BayerKerendia$20$7,95812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Potosi

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →